Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US6346249B1 · kind B1 · utility
6Cited by
8References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 4, 2000 |
| Grant date | Feb 12, 2002 |
| Priority date | — |
| Expiry date | Apr 4, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to methods of reducing the effects of cancer in a subject by administering to said subject a pharmaceutically effective amount of an anti-cancer agent conjugated to an inmmunoglobulin product which comprises one or more novel complementarity determining region and framework regions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.